Cancer Survivorship Research Should Aim to Enhance Quality of Life
June 1st 2002ST. PETERSBURG, Florida-As cancer survival increases, outcomes research must focus on both quality of life and length of survival, and must define and quantify late effects of cancer treatment, Noreen Aziz, MD, PhD, MPH, said at the Late Effects of Normal Tissues (LENT) IV workshop on late effects criteria and applications.
Ingredient in Red Wine Enhances Tumor Cell Death
June 1st 2002SAN FRANCISCO-When combined with TRAIL (TNF-related apoptosis-inducing ligand), resveratrol-an antioxidant and anti-inflammatory flavinoid found in red wine-promotes apoptosis in a variety of cancers, including difficult-to-treat brain cancers, according to a study presented at the 93rd Annual Meeting of the American Association for Cancer Research (abstract 4238).
RhoC May Be a Marker for Small, Aggressive Breast Cancers
June 1st 2002SAN FRANCISCO-Complete axillary lymph node dissection followed by chemotherapy is standard treatment for larger breast tumors, but it is less frequently performed when the tumor is smaller than 1 cm. Still, approximately 5% to 8% of these small breast tumors are very aggressive. Currently, there is no way to identify which of these small tumors are more likely to metastasize and thus should receive more appropriate treatment.
Hypothyroidism Enhances High-Dose Tamoxifen in Glioma
June 1st 2002SAN FRANCISCO-Although tamoxifen (Nolvadex) kills glioma cells in culture, it has not been effective in prolonging survival in patients with recurrent glioma. A study presented at the 93rd Annual Meeting of the American Association for Cancer Research (abstract 2442), however, found that pretreating with propylthiouracil and Lugol’s solution (a solution of potassium iodide and iodine) to induce chemical hypothyroidism prior to high-dose tamoxifen therapy resulted in dramatic increases in survival time in these patients.
Aerobic Exercise Reduces Bone Wasting in Patients Receiving Chemotherapy
June 1st 2002PORTLAND,Oregon-Aerobic exercise can sharply reduce the bone-wasting effects of chemotherapy, according to Anna L. Schwartz, PhD, associate professor and research scientist at the Oregon Health and Science University School of Nursing in Portland. Osteoporosis is becoming an increasingly common and troublesome side effect of chemotherapy, particularly in breast cancer, she reported. In addition to the treatment regimens, premature menopause and inactivity all contribute to a decline in bone mineral density (BMD). Aerobic exercise can reduce this decline and help prevent treatment-related weight gain while increasing muscle strength.
Antibiotic Inhibits Key Protein in Two Cancer Cell Pathways
June 1st 2002NEW YORK-A drug that targets a protein important to two cancer cell pathways will be tested in combination with paclitaxel (Taxol) in phase II clinical trials slated to begin soon at Memorial Sloan-Kettering Cancer Center and the Mayo Clinic, Neal Rosen, MD, PhD, said at a "Meet the Experts" media briefing sponsored by the American Society of Clinical Oncology.
Molecular Targeting Offers Specific Drugs for Specific Cancers
June 1st 2002BETHESDA, Maryland-The understanding of carcinogenesis that has emerged from molecular and genetic studies has provided a new vision of treatment, commonly called molecular targeting. In it, debilitating cytotoxic drugs will give way to agents that target specific proteins that mark specific cancer cells.
InTouch Indexed in Medline and Index Medicus
June 1st 2002InTouch magazine, a sister publication of ONCOLOGY and Oncology News International, has been selected by the National Library of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.
New Outpatient Screening Tool Pinpoints Problems During Cancer Treatment
June 1st 2002BALTIMORE-Medical personnel are often "dreadful" at singling out individuals facing mood disturbances, emotional issues, and practical problems that can cause severe distress during cancer treatment, according to Matthew Loscalzo, MSW, director of patient and family services and co-director of oncology pain services at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. A new screening and assessment tool used at the onset of treatment, however, identifies the issues most important to each individual patient and allows staff to promptly arrange for needed services, he told an industry-sponsored symposium held in conjunction with the Oncology Nursing Society annual meeting.
Anemia Is an Important, But Often Ignored, Cause of Fatigue in Cancer Patients
June 1st 2002BALTIMORE-Fatigue is a universally recognized complication of cancer, caused by both the disease itself and its treatment, but the role of anemia in causing fatigue has received insufficient attention, according to MiKaela Olsen, RN, MS. This oversight has led to undertreatment of anemia, but proper evaluation and treatment can reduce anemia and the fatigue and other troubling symptoms it causes, she said at an industry-sponsored symposium held in conjunction with the Oncology Nursing Society annual meeting. Ms. Olsen is an oncology/bone marrow transplant/hematology clinical nurse specialist at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore.
Aromatherapy Massage Studies Show Promising Quality of Life Results
June 1st 2002NEW YORK-Aromatherapy massage reduces short-term anxiety in cancer patients, improves quality of life (QOL), and is perceived by cancer patients as being beneficial, according to results to date from evaluations conducted by researchers in the United Kingdom.
The Health Economics of Palliative Care
June 1st 2002Payne, Coyne, and Smith present a concise review of the surprisingly meager literature regarding costs of end-of-life cancer care, an issue with substantial ethical and financial implications. They present evidence that improved coordination of care holds the potential to lower costs, or at least to offer better services at the same cost. The authors are to be commended for pursuing more rigorous studies regarding this difficult-to-quantify area of medical and social services. Moreover, they appropriately highlight the difficulties in attempting to capture direct costs of medical care and the far more elusive indirect costs.
Current Clinical Trials in Non-Hodgkin’s Lymphoma
June 1st 2002The non-Hodgkin’s lymphomas (NHL) are the fifth most common cause of cancer in men and women in the United States, and the fifth and sixth leading causes of cancer deaths, respectively. Approximately 54,000 new cases are projected to be diagnosed in the United States this year,[1] 25% to 30% of which are indolent histologies, with the remainder being aggressive tumors.
Treatment of Dyspnea in Cancer Patients
June 1st 2002A 54-year-old female seeks medical attention with a complaint of worsening exertional dyspnea of 3 to 4 weeks’ duration. She has a history of small-cell lung carcinoma, first diagnosed 3 months previously, and has had an excellent response to treatment, which included both chemotherapy and external-beam radiation. Consistent with her cancer diagnosis, she has a 30 pack-year history of cigarette smoking, and her pulmonary function tests indicate mild airflow obstruction, slight hyperinflation on lung volumes, and a mildly decreased diffusion capacity. In addition to her dyspnea with exertion, the patient describes symptoms of an intermittently productive cough, fatigue, and, recently, a poor appetite.
Key Challenge for Antitobacco Activists
June 1st 2002I read with interest the commentary by Drs. Michael S. Givel and Stanton A. Glantz, regarding state-level disbursement of monies generated by the Master Settlement Agreement with Big Tobacco, which appeared in the February 2002 issue of ONCOLOGY.[1] Unfortunately, the authors omitted the key challenge facing antitobacco activists. Although they accurately depicted underfunding of tobacco control programs (~5% of total annual allocated payments)-far lower than levels recommended by the Centers for Disease Control and Prevention (~25%)[2]-they failed to analyze the deceptive nature of how the remaining funds are being categorized.
Treatment of Dyspnea in Cancer Patients
June 1st 2002Dyspnea is an extremely common symptom among cancer patients.[1] Like pain, it is inherently subjective and is best defined as the perception of difficulty in breathing, or an uncomfortable awareness of breathing. Although it may be associated with one or more physiologic disturbances (such as hypercapnia, hypoxia, obstructive or restrictive patterns on pulmonary function tests, or various abnormalities on chest imaging studies), it is not strongly associated with any specific abnormality and may occur in the absence of any. Patient self-report is the gold standard for assessment and may range from mild breathlessness on exertion to a terrifying sense of suffocation.
Integration of Docetaxel Into Adjuvant Breast Cancer Treatment Regimens
June 1st 2002Adjuvant chemotherapy is an integral component of the multidisciplinary curative treatment of primary breast cancers. The experience of the last 3 decades indicates that anthracycline-containing regimens provide the most effective cytotoxic treatment for this purpose.
Current Perspectives on Pain in AIDS, Part 1
June 1st 2002As active participants in the care of patients with acquired immunodeficiency syndrome (AIDS), oncologists need to be aware of the many facets of pain management in this population. This two-part article, which will conclude in the July 2002 issue, describes the prevalence and types of pain syndromes encountered in patients with AIDS, and reviews the psychological and functional impact of pain as well as the barriers to adequate pain treatment in this group and others with human immunodeficiency virus (HIV)-related disease.
Low but Real Risk of Lymphedema Reported After Sentinel Lymph Node Biopsy
June 1st 2002EVANSTON, Illinois-Although biopsy of sentinel lymph nodes is often considered an almost risk-free procedure in the staging of breast cancer, a retrospective chart review showed a surprising incidence of lymphedema associated with this procedure. Carole H. Martz, RN, MS, and colleagues at Evanston Northwestern Healthcare in Illinois reported a 3% risk of lymphedema after sentinel lymph node biopsy (SNLB, n = 303), compared to a 17% risk after axillary dissection (n = 117).
Panel Creates ‘Single Language’ for Grading Delayed Effects
June 1st 2002ST. PETERSBURG, Florida-New cancer regimens are sometimes a double-edged sword, offering better survival but also delayed toxicity affecting quality of life. At the Late Effects of Normal Tissues (LENT) IV workshop, an international, multidisciplinary panel tackled the Herculean task of defining, grading, and reporting chronic toxicity. The workshop included representatives from more than 10 countries, including two European organizations.
Prognosis Good for Local Recurrence After Lumpectomy
May 1st 2002SAN ANTONIO-Patients who develop a local recurrence after conservative surgery and radiation therapy for early-stage breast cancer generally have a good long-term prognosis, particularly if treated with mastectomy, lead researcher Sharon Galper, MD, told ONI. In this study, 59% of patients with a local recurrence were alive at 10 years, said Dr. Galper, assistant professor of radiation oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School.
Long-Term Use of Actiq Safe and Effective for Breakthrough Pain
May 1st 2002BALTIMORE-For cancer patients with breakthrough pain, oral transmucosal fentanyl (Actiq) continues to provide good relief with long-term use, Richard Payne, MD, said at the 21st Annual Scientific Meeting of the American Pain Society (abstract 770).
Youth Exposed to Tobacco Promotions
May 1st 2002WASHINGTON-Young people are frequently exposed to high levels of tobacco promotion despite current advertising restrictions, and a new report from the Centers for Disease Control and Prevention says such advertising exists in more than 90% of retail stores selling tobacco products.
Green Tea May Help Prevent Certain Gastrointestinal Cancers
May 1st 2002SAN FRANCISCO-Retrospective and laboratory studies have suggested that green tea might be useful for both the prevention and treatment of cancer. Two presentations at the 93rd Annual Meeting of the American Association for Cancer Research, however, showed conflicting results on the effectiveness of this beverage as an anticarcinogenic agent.
Anxiety, Depression in Women at High Risk for Breast Cancer
May 1st 2002A substantial minority of the women who see themselves as being at high risk for breast cancer because of family history suffer noticeable depressive symptoms and anxiety, and the anxiety can interfere with compliance with recommendations on breast self-examination (BSE), according to studies at the UCLA Revlon Breast Center.
Danny Glover ‘Acting’ as Spokesman for Anemia LifeLine
May 1st 2002NEW YORK-Actor Danny Glover is serving as spokesman for Anemia LifeLine, a new educational initiative. Mr. Glover’s father had anemia associated with chronic kidney disease. At a press conference to launch the initiative, Mr. Glover told how anemia had robbed his father James Glover of his desire to do the things he loved. He said his father was ready to give up, but treatment gave him back his energy and independence.
Health Care Spending Expected to Soar
May 1st 2002WASHINGTON-Heath care spending is projected to more than double in the coming decade. The projected figure for 2011 is $2.8 trillion, up from $1.3 trillion in 2000, and the expected average annual growth rate is 7.3%, according to the Centers for Medicare and Medicaid Services.